Gabriel Etienne

Gabriel Etienne

UNVERIFIED PROFILE

Are you Gabriel Etienne?   Register this Author

Register author
Gabriel Etienne

Gabriel Etienne

Publications by authors named "Gabriel Etienne"

Are you Gabriel Etienne?   Register this Author

72Publications

2792Reads

16Profile Views

Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years.

Br J Haematol 2020 Feb 19. Epub 2020 Feb 19.

Pôle de santé publique, Unité d'Epidémiologie Clinique (USMR) & CIC-EC 14-01, CHU de Bordeaux, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16408DOI Listing
February 2020

Novel analytical methods to interpret large sequencing data from small sample sizes.

Hum Genomics 2019 08 30;13(1):41. Epub 2019 Aug 30.

Laboratory of Mammary and Leukaemic Oncogenesis, Inserm U1218 ACTION, Bergonié Cancer Institute, University of Bordeaux, 146 rue Léo Saignat, bâtiment TP 4ème étage, case 50, 33076, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40246-019-0235-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717342PMC
August 2019

Necrobiotic xanthogranuloma: a paraneoplastic skin lesion of haematological malignancies?

Eur J Dermatol 2018 Jun;28(3):384-386

Department of Vascular Medicine, INSERM CIC 1414, 35033 Rennes Cedex 9, France, Université de Rennes 1, INSERM CIC 1414, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2018.3256DOI Listing
June 2018

What is treatment free remission in chronic myeloid leukemia?

Oncotarget 2018 Jan 18;9(4):4279. Epub 2017 Dec 18.

Institut Bergonie Cancer Center, Department of Hematology, Universite Bordeaux, Bordeaux, Aquitaine, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.23398DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796972PMC
January 2018

Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML.

Blood 2017 08 13;130(6):832-835. Epub 2017 Jun 13.

Département d'Hématologie et Immunologie Biologiques, Hôpitaux Universitaires Henri Mondor APHP, Créteil, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-04-779579DOI Listing
August 2017

No, treatment for CML should not continue indefinitely.

Clin Adv Hematol Oncol 2017 Jun;15(6):489-494

University of Bordeaux, Bordeaux, France.

View Article

Download full-text PDF

Source
June 2017

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

J Clin Oncol 2017 Jan 31;35(3):298-305. Epub 2016 Oct 31.

Gabriel Etienne and François-Xavier Mahon, Institut Bergonié, Bordeaux; Joëlle Guilhot and François Guilhot, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers; Delphine Rea, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP); Bruno Varet, Hôpital Necker, AP-HP et Université Paris Descartes, Paris; Françoise Rigal-Huguet, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse; Franck Nicolini, Centre Hospitalier Lyon Sud, Pierre Bénite; Aude Charbonnier, Institut Paoli Calmette, Marseille; Agnès Guerci-Bresler, CHU Brabois Vandoeuvre, Nancy; Laurence Legros, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice; Martine Gardembas, CHU d'Angers, Angers; Viviane Dubruille, CHU Hôtel-Dieu, Nantes; Michel Tulliez, Hôpital Henri Mondor, Créteil; Marie-Pierre Noel, Hôpital Claude Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille; Jean-Christophe Ianotto, CHU Morvan, Brest; Bruno Villemagne, Centre Hospitalier Départemental La Roche-Sur-Yon, La Roche-Sur-Yon; Martin Carré, Hôpital Albert Michallon, CHU de Grenoble, Grenoble; Philippe Rousselot, Hôpital André Mignot, Le Chesnay; and François-Xavier Mahon, CHU de Bordeaux, INSERM U1218, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2914DOI Listing
January 2017

JAK2V617F and CALR double mutations are more frequently encountered in patients with low JAK2V617F allelic burdens.

Leuk Lymphoma 2016 08 4;57(8):1949-51. Epub 2016 Jan 4.

a Laboratoire d'Hématologie , CHU de Bordeaux ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1116122DOI Listing
August 2016

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.

J Clin Oncol 2016 Jan 23;34(2):151-9. Epub 2015 Nov 23.

Holly Geyer, Robyn Scherber, Heidi Kosiorek, Amylou C. Dueck, and Ruben A. Mesa, Mayo Clinic, Scottsdale, AZ; Jean-Jacques Kiladjian, Hospital Saint-Louis, Paris; Francoise Boyer, Centre Hospitalier Universitaire, Angers; Gabriel Etienne, Institut Bergonie, Bordeaux; Jean-Christophe Ianotto, Centre Hospitalier Universitaire, Brest; Dana Ranta, Centre Hospitalier Universitaire, Grenoble; Lydia Roy, Centre Hospitalier Universitaire, Poitiers; Jean-Yves Cahn, Centre Hospitalier Universitaire, Grenoble, France; Zhijian Xiao, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, and Peihong Zhang, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; Stefanie Slot and Sonja Zweegman, VU University Medical Center, Amsterdam; Peter A.W. te Boekhorst, Erasmus Medical Center, Rotterdam; Suzan Commandeur, Leiden University Medical Center, Leiden; Harry Schouten, Maastricht University Medical Center, Maastricht, the Netherlands; Frederico Sackmann, Fundaleu, Buenos Aires, Argentina; Ana Kerguelen Fuentes and Dolores Hernández-Maraver, University Hospital La Paz, Madrid; Carlos Besses, Hospital del Mar; Francisco Cervantes, University of Barcelona, Barcelona, Spain; Konstanze Döhner and Frank Stegelmann, University Hospital of Ulm; Karin Bonatz and Andreas Reiter, Universitätsmedizin Mannheim, Mannheim; Heike L. Pahl, University Hospital Freiburg, Freiburg; Martin Griesshammer, Johannes Wesling Klinikum Minden, Germany; Claire N. Harrison and Deepti Radia, Guy's and St Thomas NHS Foundation Trust; Robert Peter Gale, Imperial College, London, United Kingdom; Pablo Muxi, Hospital Británico, Montevideo, Uruguay; Peter L. Johansson and Bjorn Andreasson, NU Hospital Organization, Uddevalla; Gunnar Birgegard, University Hospital, Uppsala; Jan Samuelsson, Stockholm South Hospital, Stockholm, Sweden; Alessandro Rambaldi, Tiziano Barbui, and Maria L. Ferrari, Ospedali Riuniti di Bergamo, Bergamo; Giovanni Barosi, IRCCS Policlinico S. Matteo Foundation; Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.9337DOI Listing
January 2016

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

J Clin Oncol 2014 Feb 9;32(5):424-30. Epub 2013 Dec 9.

Philippe Rousselot, Hôpital Mignot, Université Versailles Saint-Quentin-en-Yvelines, Versailles; Aude Charbonnier, Institut Paoli Calmette, Marseille; Pascale Cony-Makhoul, Hôpital d'Annecy, Pringy; Philippe Agape, Hôpital Felix Guyon-Centre Hospitalier Universitaire en France (CHU) de la Réunion, La Réunion; Franck E. Nicolini, Centre Hospitalier Lyon Sud, Pierre-Bénite; Bruno Varet, Hôpital Necker, Assistance Publique-Hopitaux de Paris (AP-HP) et Université Paris Descartes; Delphine Réa and Jean Michel Cayuela, Hôpital Saint-Louis, AP-HP, Paris; Martine Gardembas, CHU d'Angers, Angers; Gabriel Etienne and Josy Reiffers, Institut Bergonié; François-Xavier Mahon, Hôpital Haut-Levèque et Université Bordeaux Ségalen, Bordeaux; Lydia Roy, Joëlle Guilhot, and François Guilhot, Institut National de la Santé et de la Recherche Médicale (INSERM) Centres d'Investigation Clinique CHU de Poitiers, Poitiers; Martine Escoffre-Barbe, Centre Hospitalier Pontchaillou, Rennes; Agnès Guerci-Bresler, CHU Brabois Vandoeuvre, Nancy; Michel Tulliez, Hôpital Henri Mondor, AP-HP, Créteil; Stéphane Prost, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Institute of Emerging Diseases and Innovative Therapies, Fontenay-aux-Roses; Marc Spentchian, Hôpital Mignot, Le Chesnay; and Jean Claude Chomel and Ali Turhan, INSERM U935, Université Poitiers et Paris Sud, Le Kremlin Bicêtre, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.48.5797DOI Listing
February 2014

Deep molecular response in chronic myeloid leukemia: the new goal of therapy?

Clin Cancer Res 2014 Jan 28;20(2):310-22. Epub 2013 Oct 28.

Authors' Affiliations: Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Bordeaux and Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique, Biothérapies des maladies génétiques et cancers, Inserm U1035, Université Bordeaux Ségalen; and Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest, Institut Bergonié, Département d'Oncologie Médicale, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1988DOI Listing
January 2014

Identification of methylguanine methyltransferase polymorphisms as genetic markers of individual susceptibility to therapy-related myeloid neoplasms.

Eur J Cancer 2014 Jan 14;50(2):418-24. Epub 2013 Nov 14.

INSERM U916, Bordeaux, France; Department of Medical Biology, Institut Bergonié, Bordeaux, France; Université Bordeaux Segalen, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.10.012DOI Listing
January 2014

Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells.

Blood 2011 Aug 5;118(8):2211-21. Epub 2011 Jul 5.

Hématopoïèse Leucémique et Cible Thérapeutique, Inserm U1035, Université Victor Ségalen, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-10-313692DOI Listing
August 2011

[Chronic myeloid leukemia and targeted therapies: too many choices?].

Med Sci (Paris) 2010 Nov;26(11):911-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1051/medsci/20102611911DOI Listing
November 2010

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.

Cancer Res 2008 Dec;68(23):9809-16

Hématopoïèse Leucémique et Cible Thérapeutique, INSERM U876, Université Victor Ségalen, Laboratoire d'hématologie CHU de Bordeaux, Bordeaux cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-08-1008DOI Listing
December 2008

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

Blood 2008 Sep 4;112(5):2024-7. Epub 2008 Jun 4.

Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique, Université Victor Ségalen Bordeaux 2, Inserm U876, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2008-03-147744DOI Listing
September 2008

CD8+HLA-DR+ T lymphocytes are increased in common variable immunodeficiency patients with impaired memory B-cell differentiation.

Clin Immunol 2006 Apr 18;119(1):51-8. Epub 2006 Jan 18.

Department of Internal Medicine and Infectious Diseases, Haut-Lévêque Hospital, 5, avenue Magellan, 33604 Pessac, France.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S152166160500368
Publisher Site
http://dx.doi.org/10.1016/j.clim.2005.11.011DOI Listing
April 2006

[Celiac disease and autoimmune diseases or systemic disease. Six cases and a review of the literature].

Ann Med Interne (Paris) 2003 Sep;154(4):197-204

Service des Maladies du Sang, Centre François-Magendie, CHU du Haut-Lévêque, 33604 Pessac.

View Article

Download full-text PDF

Source
September 2003

A SIN lentiviral vector containing PIGA cDNA allows long-term phenotypic correction of CD34+-derived cells from patients with paroxysmal nocturnal hemoglobinuria.

Mol Ther 2003 Mar;7(3):304-16

INSERM E 0217, Laboratoire de Pathologie Moléculaire et Thérapie Génique, Université Victor Segalen Bordeaux 2, 146 Rue Léo Saignat, 33076 Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1525-0016(03)00011-xDOI Listing
March 2003

Imatinib mesylate and gray hair.

N Engl J Med 2002 Aug;347(6):446

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJM200208083470614DOI Listing
August 2002